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Background: In addition to the regulation of calcium homeostasis, vitamin D affects the cellular immune system, 
targets the TNF-α pathway and increases vasoconstrictor response to angiotensin II. We therefore examined the 
effect of 1,25-dihydroxy-vitamin D3 on coagulation and organ failure in experimental sepsis in the rat. 
Methods: Three series of placebo-controlled studies were conducted. All rats were pre-treated with daily SC in-
jections of 1,25-dihydroxy-vitamin D3 100 ng/kg or placebo vehicle for 3 days. In study 1, sepsis was accom-
plished by abdominal surgery comprising a coecal ligation and puncture with a 1,2 mm needle, or sham surgery. 
In study 2, the rats had a single IP injection of lipopolysaccharide from E. Coli 0111:B4 (LPS) 8 mg/kg, or placebo. 
In study 3, an hour-long IV infusion of LPS 7 mg/kg, or placebo was given. 
Results: All three models of sepsis showed significant effects on coagulation and liver function with reduced 
thrombocyte count and prothrombin time together with elevated ALT and bilirubin (p<0.05) as compared to 
controls. In study 1, the vitamin D treated rats maintained normal platelet count, whereas the vehicle treated rats 
showed a significant reduction (p<0.05). This effect of vitamin D on platelets was not found in the LPS-treated 
groups. We found no significant differences between vitamin D and placebo-treated rats with regards to liver 
function.  
Conclusion: The present data suggest a positive modulating effect of 1,25-dihydroxy-vitamin D3 supplementation 
on sepsis-induced coagulation disturbances in the coecal ligation and puncture model. No such effect was found 
in LPS-induced sepsis. 
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1.  Introduction 
The hormonally active form of vitamin D, 
1,α25-dihydroxyvitamin D3 (1,25-vit D) is an impor-
tant regulator of the calcium-phosphate homeostasis. 
In addition, this compound possesses a number of 
non-calcaemic effects. These include an effect on the 
immune system cell differentiation and the interaction 
of macrophages and monocytes and regulation of 
lymphocyte activity [1].   
Sepsis may be complicated by a variety of condi-
tions such as disseminated intravascular coagulation 
(DIC), circulatory collapse and multiple organ failure. 
DIC is characterized by simultaneous micro thrombo-
sis and expenditure of clotting factors causing in-
creased bleeding tendency and organ failure. Mono-
cytes play an important role in the induction of tis-
sue-factor expression [2], which is seen as a key event 
in the development of DIC in septic patients. There-
fore, there is reason to expect that 1,25-vit D could be 
useful in the treatment of DIC caused by sepsis. 
1,25-vit D also targets the TNF-a pathway to 
suppress experimental bowel disease[3] and increases 
the vasoconstrictor response to noradrenalin and an-
giotensin II [4] . Recently, evidence has emerged that 
vitamin D also enhances the function of the innate 
immune system by stimulating the formation of the 
cathelicidin antimicrobial peptide [5]. Theoretically, 
treatment with 1,25-vit D may therefore also reduce 
the septic response to intestinal perforation and reduce 
the circulatory effect of the septic condition. 
Only two studies have previously addressed this 
potential association, and both showed a beneficial 
effect of 1,25-vit D against lipopolysaccharide 
(LPS)-induced DIC in rat models [6,7]. In the present 
study, we aimed to demonstrate a possible effect of 
1,25-vit D in three different models of experimental 
sepsis and DIC in rats, using a controlled and clinically 
relevant administration of vitamin D. 
2.  Material and methods 
Animals 
Male Wistar rats weighing 300 g were obtained 
from Charles River, Sulzfeld, Germany and were kept 
in plastic cages in a controlled environment with a 
12-hour light/dark cycle and a constant temperature 
(22º C) and humidity (70%), with free access to food 
and water. The diet was Altromin 1324 (Altromin 
GmbH, Lage, Germany). The experimental studies on 
rats were performed in accordance with the NIH 
Guide for the Care and Use of Laboratory Animals and 
was approved by the local ethics committee for re-Int. J. Med. Sci. 2007, 4 
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search on animals. The rats were anaethetized by ei-
ther fentanyl-midazolam for abdominal surgery or by 
pentobarbital for LPS infusion. Postoperative analgesia 
was provided with buprenorphin. All animals were 
euthanized immediately after blood sampling. 
Materials 
1,25-dihydroxyvitamin D3 was a gift from Leo 
Pharmaceuticals (Ballerup, Denmark) and was dis-
solved in a vehicle consisting of water/propylene 
glycol/ethanol 50/40/10. The dose of 
1,25-dihydroxyvitamin D3 of 100 ng/kg/day was 
shown in previous studies from our laboratory to be 
the highest dose not causing hypercalcemia [8] . 
Lipopolysaccharide from E. Coli 0111:B4 was obtained 
from Sigma Chemicals (St. Louis, MO, USA). 
Analytical methods 
Thrombocytes were counted on a Sysmex Kx-21 
(Sysmex Corp, Mundelei, IL, USA), prothrombin, ALT, 
bilirubin, creatinine and urea were measured on an 
ACL 9000 (Instrumentation Laboratory, Lexington, 
MA, USA) kindly provided by ILS Scandinavia, and 
ionized calcium was measured on an ABL 77 (Radi-
ometer, Bronshoj, Denmark). The blood to be used for 
measurement of coagulation parameters were sampled 
directly in a citrate dilution (9:1) to avoid early coagu-
lation. Data were analyzed using non-parametric 
analysis of variance. All data are shown as the mean ± 
confidence interval. P values < 0.05 were considered 
statistically significant. 
Study design  
Three series of studies were conducted. In studies 
1 and 2, which were conducted simultaneously, 
groups 1 and 2 were identical but are in the following 
sections and in the tables described as separate groups 
to ease comparison between controls (not septic) and 
septic animals. 
 
Study 1 (Abdominal sepsis).  
Six groups of rats were pre-treated with daily SC 
injections of 1,25-vit D 100 ng/kg or vehicle for 3 days. 
The rats were then allocated to 6 groups:  
1. Controls + vehicle.  
2. Controls + 1,25-vit D.  
3. Sham surgery comprising laparotomy and ex-
posure of coecum but without ligation and puncture + 
vehicle. 
4. Sham surgery + 1,25-vit D.  
5. Surgery comprising a laparotomy with a coecal 
ligation and puncture with a 1,2 mm needle (CLP) + 
vehicle 
6. CLP + 1,25-vit D. 
At the end of surgery 10 ml isotonic saline was 
administered SC as early fluid resuscitation. Blood 
samples were obtained 24 h post treatment. 
 
Study 2 (24 hours chronic sepsis).  
Four groups of rats were pre-treated with daily 
SC injections of 1,25-vit D 100 ng/kg or vehicle for 3 
days. The rats were then allocated to 4 groups:  
1. Controls + vehicle.  
2. Controls + 1,25-vit D.  
3. Single IP injection of lipopolysaccharide from 
E. Coli 0111:B4 (LPS) 8 mg/kg + vehicle.  
4. Single IP injection of lipopolysaccharide from 
E. Coli 0111:B4 (LPS) 8 mg/kg + 1,25-vit D.   
10 ml isotonic saline was administered SC as 
early fluid resuscitation. Blood samples were obtained 
24 h post treatment.  
 
Study 3 (4 hours acute sepsis).  
Four groups of rats were pre-treated with daily 
SC injections of 1,25-vit D 100 ng/kg or vehicle for 3 
days. A catheter was placed in the left femoral vein 
with the use of microscopic surgery. The anaesthesia 
was maintained for the whole duration of the experi-
ment (4 hours) by supplemental administration of 
pentobarbital. The rats were allocated to 4 groups:  
1. Controls had hour-long placebo infusion of 20 
ml isotonic saline through the femoral catheter + vehi-
cle.  
2. Controls + 1,25-vit D.  
3. Hour-long IV infusion of LPS 7 mg/kg in 20 ml 
isotonic saline via a catheter in a femoral vein + vehi-
cle.  
4. Hour-long IV infusion of LPS 7 mg/kg + 
1,25-vit D. 
Blood samples were obtained 4 h post treatment.  
3.  Results 
The effect of 1,25 vit-D or vehicle on sepsis in-
duced by coecal ligation and puncture (CLP) or sham 
operation is shown in table 1. 
The CLP model induced a septic condition in the 
rats as shown by reduced thrombocyte count and in-
creased ALT and bilirubin (p<0.05). The thrombocy-
topenia was significantly counteracted in the the vi-
tamin D treated rats with thrombocytes 515 ± 53 109 /L 
as compared to 418 ± 49 109 /L in the vehicle treated 
rats (p<0.05). Plasma bilirubin showed a minor but 
significant increase from 0.68 ± 0.29 μmol/L to 1.23 ± 
0.11 μmol/L among the sham operated rats, this was 
however counteracted in the 1,25 vit-D treated sham 
operated rats to 0.73 ± 0.39 μmol/L (p<0.05). This effect 
of 1,25 vit-D was also found among the CLP operated 
animals where the bilirubin value increased to 3.51 ± 
1.87  μmol/L, but among the 1,25 vit-D treated and 
CLP operated bilirubin only increased to 2.36 ± 1.14 
μmol/L. This difference did not reach statistical sig-
nificance due to high variance of data. Plasma ALT 
levels increased among both sham operated and CLP 
operated rats. The ALT elevation was only significant 
among the 1,25-vit D treated CLP operated rats. No 
significant differences were found in the measuremets 
of PT, creatinine, or urea. Ionized calcium values were 
significantly reduced in LPS treated rats (p<0.05), and 
no difference in ionized calcium values was found 
between 1,25-vit D or vehicle treated rats. 
The effect of 1,25 vit-D or vehicle on chronic sep-
sis induced by single IP injection of LPS is shown in Int. J. Med. Sci. 2007, 4 
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table 2. 
The LPS injection induced a septic condition in 
the rats with effects on coagulation and liver function 
as shown by reduced thrombocyte count and increased 
ALT and bilirubin (p<0.05). We found no differences in 
thrombocyte count, ALT and bilirubin between con-
trols receiving 1,25 vit-D or vehicle, and we found no 
differences in PT and creatinine between controls and 
LPS treated rats. Plasma urea increased from 8.2 ± 0.5 
mmol/L in the control rats in group 1 to 11.9 ± 2.5 
mmol/L among the 1,25 vit-D and LPS treated rats 
(p<0.05), but no difference was demonstrated between 
the rats that received LPS and either vehicle or vitamin 
D. Ionized calcium values were significantly reduced 
in LPS treated rats (p<0.05), and no difference in ion-
ized calcium values was found between 1,25-vit D or 
vehicle treated rats. 
The effect of 1,25 vit-D or vehicle on acute sepsis 
induced by an hour-long infusion of LPS is shown in 
table 3. 
Table 1. Sepsis accomplished by abdominal surgery comprising coecal ligation and puncture with a 1,2 mm needle (CLP), or sham 
surgery + pre-treatment with 1,25 vit-D or vehicle. 
  Control 
+vehicle 
Control 
+  
1,25 vit-D 
Sham- 
operation 
+vehicle 
   S h a m -  
operation  
+ 1,25 vit-D 
CLP 
+vehicle 
CLP 
+ 1,25 vit-D 
n=  8 8 8  8  8  8 
Thrombocytes 
(109/L) 
647 ± 95 
 
606 ± 139  631 ± 48  551 ± 53  418 ± 49 b  515 ± 53 c 
PT 
(seconds) 
12,0 ± 0,2  12,2 ± 0,7 
 
11,4 ± 0,6  11,0 ± 0,8  12,5 ± 1,2  12,7 ± 1,0 
 
ALT 
(units/L) 
53 ± 7 
 
53 ± 8  59 ± 13  64 ± 5  71 ± 17 
 
77 ± 13 b 
Bilirubin 
(µmol/L) 
0,68 ± 0,29 
 
0,62 ± 0,27  1,23 ± 0,11 a  0,73 ± 0,39 c  3,51 ± 1,87 b 
 
2,36 ± 1,14 b 
Creatinine 
(µmol/L) 
41 ± 7 
 
46 ± 19  46 ± 14  36 ± 3  40 ± 2 
 
42 ± 5 
Urea 
(µmol/L) 
8,2 ± 0,5 
 
8,4 ± 0,7  7,0 ± 0,5 a  6,5 ± 0,6 a  6,9 ± 0,8 
 
8,9 ± 2,6 
Ca++(7,4) 
(mmol/L) 
1,34 ± 0,02  1,36 ± 0,02  1,35 ± 0,02  1,35 ± 0,02  1,26 ± 0,06 b  1,28 ± 0,03 b 
a Significant effect of sham operation vs control. (P<0,05) 
b Significant effect of CLP vs. sham operation.  (P<0,05) 
c Significant effect of 1,25 vit-D vs. vehicle.   (P<0,05). 
Table 2. Sepsis accomplished by a single IP injection of lipopolysaccharide from E. Coli 0111:B4 8 mg/kg (LPS), or control + 
pre-treatment with 1,25 vit-D or vehicle. 
  Controls 
+vehicle 
Controls 
+1,25 vit-D 
LPS    
+ vehicle 
LPS  
+1,25 vit-D 
n=  8 8 6  6 
Thrombocytes 
(109/L) 
647 ± 95 
 
606 ± 139  259 ± 198 a 
 
208 ± 214 a 
PT 
(seconds) 
12,0 ± 0,2  12,2 ± 0,7 
 
11,4 ± 0,4 a  12,0 ± 0,4 
ALT 
(units/L) 
53 ± 7 
 
53 ± 8  124 ± 167  94 ± 24 a 
Bilirubin 
(µmol/L) 
0,68 ± 0,29 
 
0,62 ± 0,27  1,77 ± 1,10  2,12 ± 0,53 a 
Creatinine 
(µmol/L) 
41 ± 7 
 
46 ± 19  44 ± 7  57 ± 11 
urea 
(µmol/L) 
8,2 ± 0,5  8,4 ± 0,7  10,66 ± 3,09  11,90 ± 2,47 a 
Ca++(7,4) 
(mmol/L) 
1,34 ± 0,02  1,36 ± 0,02  1,36 ± 0,02  1,37 ± 0,02 
a Significant effect of LPS vs control. (P<0,05). 
No significant effects (P<0,05) of 1,25 vit-D were seen in this study.  
Table 3. Sepsis accomplished by an hour-long IV infusion of lipopolysaccharide from E. Coli 0111:B4 7 mg/kg (LPS), or control + 
pre-treatment with 1,25 vit-D or vehicle.  
  Control 
+vehicle 
Control 
+ 1,25 vit-D 
LPS    
+ vehicle 
LPS   
+ 1,25 vit-D 
n=  6 8  10 10 
Thrombocytes 
(109/L) 
1056 ± 196  980 ± 260  480 ± 80 a  415 ± 63 a 
PT 
(seconds) 
21,4 ± 3,5  17,9 ± 2,0  29,8 ± 6,1  26,6 ± 3,6 a 
ALT 
(units/L) 
53 ± 18  78 ± 30 
 
66 ± 8  93 ± 33 Int. J. Med. Sci. 2007, 4 
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Bilirubin 
(µmol/L) 
1,27 ± 0,35  1,27 ± 0,13 
 
2,66 ± 0,65 a  3,26 ± 0,60 a 
Creatinine 
(µmol/L) 
55 ± 4  62 ± 5 b 
 
76 ± 6 a  103 ± 19 a,b 
Urea 
(µmol/L) 
6,3 ± 1,1  7,8 ± 0,7 
 
11,8 ± 0,8 a  13,3 ± 1,0 a,b 
Ca++(7,4) 
(mmol/L) 
1,34 ± 0,02  1,42 ± 0,05 b  1,24 ± 0,04 a  1,28 ± 0,04 a 
a Significant effect of LPS vs. controls.    (P<0,05) 
b Significant effect of 1,25 vit-D vs. vehicle.   (P<0,05). 
 
The LPS infusion induced a septic condition in 
the rats with effect on coagulation and liver function as 
shown by reduced thrombocyte count and increased 
bilirubin (p<0.05). ALT values did not increase in the 
short 4 hours observation time, but in this model renal 
failure occurred as expressed by significantly elevated 
creatinine and urea values in the LPS treated rats 
(p<0.05). The 1,25-vit D treated rats developed higher 
values of creatinine and urea than the vehicle treated 
rats (p<0.05) indicating a higher level of renal suscep-
tibility to sepsis after 1,25 vit-D administration. Ionized 
calcium values were significantly reduced in LPS 
treated rats (p<0.05), and no difference in ionized cal-
cium values was found between 1,25-vit D or vehicle 
treated rats. 
The mortality rate in the present study was low. 
In study 1, all rats survived. In study 2, Two out of 8 
rats died in both LPS + 1,25 vit-D and in LPS + vehicle 
groups. In study 3, due to the expected mortality, 8 rats 
were included in both control groups and 10 in both 
LPS-infused groups. However, no animals died in the 
observation period in the LPS infused groups, whereas 
2 animals died in the control + vehicle group.  
4.  Discussion 
1,25 (OH)2 vitamin D3 regulates the differentia-
tion from stem cells towards monocytes and macro-
phages by interacting with specific vitamin D receptors 
in the myeloid tissue cells [9,10]. The macrophages 
themselves produce and excrete this active form of 
vitamin D and, therefore, by both autocrine and 
paracrin stimulation influence their own macrophage 
activity in addition to the T- and B-lymphocyte dif-
ferentiation and activity [11,12,13]. 
The inflammatory cytokines, TNF-alpha and cer-
tain interleukins play a key-role in initiating systemic 
inflammatory response syndrome (SIRS) and it is 
known that vitamin D may modulate the cytokine ex-
pression from the monocytes and macrophages, even 
though the action is complex and unclarified 
[14,15,16]. vitamin D also targets theTNF-alpha path-
way to suppress experimental inflammatory bowel 
disease [3].  
Arteriolar and myocardial walls contain specific 
vitamin D receptors, and vitamin D exerts a direct ef-
fect on the vasculature causing an enhanced effect of 
inotropic drugs [4,17]. The hemodynamic shock re-
sponse to induction of sepsis may therefore be reduced 
by administration of 1,25-vit D. 
In addition to these effects, Vitamin D may also 
inhibit the cytokines effect on target cells. vitamin D 
has an antagonistic effect on TNF-alpha stimulation of 
monocytes in cultures by down-regulating the surface 
protein tissue factor (TF) and up-regulating trombo-
modulin (TM) expression in monocytic cells [18]. 
These proteins are well-known activators and control-
lers of coagulation.  
It is therefore theoretically feasible that vitamin D 
administration may attenuate the course of sepsis in-
duced coagulation disturbances, but only two in vivo 
studies have, to our knowledge, previously tested this 
hypothesis (Horiuchi et al (1991) [6] and Asakura et al 
2001 [7]). These studies showed beneficial effects of 
vitamin D in LPS induced sepsis.   
Horiuchi [6] administered a single dose of LPS 20 
mg/kg and 1,25-vit D 20 ng/kg simultaneously to 
mice. He found an improvement in survival rate from 
0% to 39% after 48 hours and concluded that this effect 
might be a result of an inhibition of endotoxemia 
through regulation of thromboxan and hepatic 
malondialdehyd. Asakura in his work [7] administered 
1,25-vit D 2 mg/kg/day or vehicle orally for 3 days 
prior to a 4 hour infusion of E. Coli LPS in rats and 
found beneficial effects of the vitamin D metabolite on 
thrombocyte count, ALT, creatinine, and glomerular 
fibrin deposition. Asakura concluded that 1,25-vit D 
was effective in protecting against DIC in experimental 
LPS-induced shock. 
It has been argued that the experimental model of 
sepsis induced by infusion of LPS in high doses is 
unphysiological and differs from a clinical scenario 
[19], whereas other standardized setups such as the 
cecal ligation and puncture technique [19], to a greater 
degree mimic the clinical realities in sepsis. We, 
therefore, decided to duplicate the experimental pro-
tocols used by Horiuchi [6] and Asakura [7] but also to 
add an examination of a model of abdominal sepsis. To 
probe the possibility that 1,25-vit D could have thera-
peutic potential within pharmacologically safe doses, a 
previously validated dose of 1,25-vit D was chosen [8] . 
In Asakura´s study, 1,25-vit D was given orally but as 
intestinal vitamin D uptake is unpredictable, we de-
cided to administer the 1,25-vit D by subcutaneous 
injections. This study is the first of its kind, and there-
fore our main priority was to establish a potential re-
lationship between vitamin D (pre)treatment and the 
effects of sepsis. The effect of 1,25-vit D on the immune 
system and coagulation has never been time-scaled, 
and may not follow the pattern of calcium regulation. 
As the steroid hormone Vitamin D works by gene 
transcription, the effects are delayed, and could not be 
expected to be effective on an hour-to-hour basis. For 
these reasons, we chose to administer vitamin D as a 
pre-treatment to sepsis rather than an intervention.. Int. J. Med. Sci. 2007, 4 
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Apart from the addition of the surgical, abdominal 
sepsis (which has not previously been studied in rela-
tion to vitamin D) the dosage, timing and administra-
tion form of 1,25 vit-D constitute the biggest differ-
ences between this study and earlier works, and we 
attribute much of the difference in results to these fac-
tors.  
All three models of experimental sepsis in our 
study worked successfully by inducing a significant 
affection of coagulation and liver paramenters in the 
rats. The 1,25-vit D treatment caused a minor increase 
in ionized calcium levels, however this only reached a 
significant level in study 3 showing an increase from 
1.34 to 1.42 mmol/l (p<0.05). Among the septic rats, 
ionized calcium levels fell significantly in all three 
models and was unaffected by the1,25-vit D treatment. 
This is a well described pattern both in clinical and 
experimental sepsis and may be caused both by insuf-
ficient secretion and effect of parathyroid hormone in 
an acidotic environment, and by insufficient calcium 
pumps in the cellular membranes changing the bal-
ance between the intracellular low calcium and the 
extracellular high calcium values. The renal parame-
ters showed no sign of uremia after CLP, whereas LPS 
infusion caused an increase of both creatinine and urea 
surprisingly further increased among the rats that 
were pretreated with 1,25-vit D. This state of hy-
peracute sepsis may cause a higher susceptibility to 
nephrocalcinosis, which is a well described, harmful 
effect of vitamin D.  
In our study, pretreatment with 1,25-vit D re-
duced the CLP induced thrombocytopenia signifi-
cantly (p<0.05) indicating a protective role for 1,25-vit 
D against the development of sepsis induced dis-
seminated intravascular coagulation. In contrast to the 
studies by Horiuchi [6] and Asakura [7] we were un-
able to demonstrate a protective effect of 1,25-vit D 
treatment in the LPS induced sepsis.  
The pretreatment with 1,25-vit D had no protec-
tive effect on the elevation of plasma bilirubin and 
ALT. It therefore appears that the septic shock devel-
oped equally severely in both 1,25-vit D and vehicle 
treated rats, but that the secondary effect on coagula-
tion in the CLP treated rats was less severe after 
1,25-vit D treatment.  
5.  Conclusion 
The beneficial effects of vitamin D on the re-
sponse to sepsis in the present study only comprises a 
lesser development of thrombocytopenia in CLP 
treated rats. A limiting factor in exploring this subject 
further is the development of hypercalcemia by the use 
of higher doses of 1,25-vit D.  
In conclusion, the present data suggest a slightly 
positive modulating effect of 1,25-dihydroxy-vitamin 
D3 supplementation on sepsis-induced coagulation 
disturbances in the coecal ligation and puncture 
model. No such effect was found in LPS-induced sep-
sis. 
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